627 related articles for article (PubMed ID: 30266108)
1. Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy.
Ni JM; Ni AP
Chin Med Sci J; 2018 Sep; 33(3):174-182. PubMed ID: 30266108
[TBL] [Abstract][Full Text] [Related]
2. The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.
Wang Q; Lin W; Tang X; Li S; Guo L; Lin Y; Kwok HF
Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186904
[TBL] [Abstract][Full Text] [Related]
3. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen J; Jiang CC; Jin L; Zhang XD
Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
[TBL] [Abstract][Full Text] [Related]
4. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.
Hu X; Wang J; Chu M; Liu Y; Wang ZW; Zhu X
Mol Ther; 2021 Mar; 29(3):908-919. PubMed ID: 33388422
[TBL] [Abstract][Full Text] [Related]
5. Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.
Shen X; Zhang L; Li J; Li Y; Wang Y; Xu ZX
Front Immunol; 2019; 10():1337. PubMed ID: 31258527
[TBL] [Abstract][Full Text] [Related]
6. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment.
Hudson K; Cross N; Jordan-Mahy N; Leyland R
Front Immunol; 2020; 11():568931. PubMed ID: 33193345
[TBL] [Abstract][Full Text] [Related]
7. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).
Kim JM; Chen DS
Ann Oncol; 2016 Aug; 27(8):1492-504. PubMed ID: 27207108
[TBL] [Abstract][Full Text] [Related]
8. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
Zerdes I; Matikas A; Bergh J; Rassidakis GZ; Foukakis T
Oncogene; 2018 Aug; 37(34):4639-4661. PubMed ID: 29765155
[TBL] [Abstract][Full Text] [Related]
9. PD-L1/PD-1 axis as a potent therapeutic target in breast cancer.
Bastaki S; Irandoust M; Ahmadi A; Hojjat-Farsangi M; Ambrose P; Hallaj S; Edalati M; Ghalamfarsa G; Azizi G; Yousefi M; Chalajour H; Jadidi-Niaragh F
Life Sci; 2020 Apr; 247():117437. PubMed ID: 32070710
[TBL] [Abstract][Full Text] [Related]
10. Targeting PD-L1 Protein: Translation, Modification and Transport.
Wei R; Guo L; Wang Q; Miao J; Kwok HF; Lin Y
Curr Protein Pept Sci; 2019; 20(1):82-91. PubMed ID: 30264678
[TBL] [Abstract][Full Text] [Related]
11. Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway.
Wakabayashi G; Lee YC; Luh F; Kuo CN; Chang WC; Yen Y
J Biomed Sci; 2019 Dec; 26(1):96. PubMed ID: 31801525
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.
Bocanegra A; Blanco E; Fernandez-Hinojal G; Arasanz H; Chocarro L; Zuazo M; Morente P; Vera R; Escors D; Kochan G
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824655
[TBL] [Abstract][Full Text] [Related]
13. Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer.
Kowalski A; Malinowska K; Olszewski J; Zielińska-Bliźniewska H
Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356594
[TBL] [Abstract][Full Text] [Related]
14. PD-L1.
Kythreotou A; Siddique A; Mauri FA; Bower M; Pinato DJ
J Clin Pathol; 2018 Mar; 71(3):189-194. PubMed ID: 29097600
[TBL] [Abstract][Full Text] [Related]
15. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
Lu C; Paschall AV; Shi H; Savage N; Waller JL; Sabbatini ME; Oberlies NH; Pearce C; Liu K
J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131992
[TBL] [Abstract][Full Text] [Related]
16. HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.
Deng S; Hu Q; Zhang H; Yang F; Peng C; Huang C
Mol Cancer Ther; 2019 May; 18(5):900-908. PubMed ID: 30824609
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer.
Funaki S; Shintani Y; Kawamura T; Kanzaki R; Minami M; Okumura M
Oncol Rep; 2017 Oct; 38(4):2277-2284. PubMed ID: 28849209
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular characteristics associated with survival among cancer patients receiving first-line anti-PD-1/PD-L1-based therapies.
Zhou Y; Wang C; Jiang Y; Ren P; Shao J; Tuersun P; Li W
Biomarkers; 2020 Sep; 25(6):441-448. PubMed ID: 32744106
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic regulators of programmed death-ligand 1 expression in human cancers.
Kumar S; Sharawat SK
Transl Res; 2018 Dec; 202():129-145. PubMed ID: 30401465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
